Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Inks Italian Distribution Deal for GI Infection Diagnostics

NEW YORK (GenomeWeb) – Finnish molecular diagnostics firm Mobidiag announced today that it has signed an agreement making AB Analitica the exclusive distributor of its real-time PCR-based Amplidiag in vitro diagnostics in Italy.

Under the terms of the three-year deal, AB Analitica will be the sole Italian distributor of all Amplidiag tests for gastrointestinal infections — including Amplidiag H. pylori+ClariR, Amplidiag Stool Parasites, Amplidiag CarbaR+VRE, Amplidiag C. difficile+027, and Amplidiag Bacterial GE — as well as the high-throughput Amplidiag Easy system. The arrangement also includes the upcoming Amplidiag Viral GE and Amplidiag CarbaR+MCR tests.

Additional terms were not disclosed.

"In order to make our IVD tests and instruments accessible throughout Europe, we are continuing the expansion of our distributor network to be able to support our customers more locally," Mobidiag CEO Tuomas Tenkanen said in a statement.

To date, Mobidiag has signed distribution deals covering South Africa, Sweden and Norway, Portugal, the UK, and various other Eastern and Western European nations.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.